Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

Jun‐ya Kato, H Matsushime, Scott W. Hiebert et al. · Genes & Development · 1993 · 1.3K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Shi-Yong Sun, Laura M. Rosenberg, Xuerong Wang et al. · Cancer Research · 2005 · 808 citations

Medicine, Oncology, Pharmacology +13

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +17

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy et al. · Journal of Clinical Oncology · 2004 · 579 citations

Medicine, Hematology, Pharmacology +17

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

Georg Lenz, Martin Dreyling, Eva Hoster et al. · Journal of Clinical Oncology · 2005 · 573 citations · Full text

Medicine, Oncology, Pharmacotherapy +16